Compare Cassava Sciences Inc (FLNA) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Kimberly Clark Corp — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Kimberly Clark Corp trades at $97.86 (market cap $32.51B). The key difference: Kimberly Clark Corp is far larger — about 825.1× Cassava Sciences Inc's market cap, and Kimberly Clark Corp pays a 5.24% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Kimberly Clark Corp for 93 Days on average.
| FLNA | KMB | |
|---|---|---|
Market Cap | $39.40M | $32.51B |
Volume | 759,018 | 6,139,913 |
Sector | Health | Consumer Staples |
52-Week High | $4.64 | $121.44 |
52-Week Low | $0.68 | $93.05 |
Typical Hold Time | 37 Days | 93 Days |
Enterprise Value | -$43.28M | $38.07B |
Dividend Yield | — | 5.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Kimberly-Clark (KMB) trades at $96.48, down 0.3% on the day, showing bearish technical signals with recent price weakness. The company maintains strong profitability with 11.79% net margins and 129.43% ROE, though revenue declined to $16.45B in 2025. Recent Q2 2026 earnings missed expectations, while analyst consensus remains cautiously optimistic with a $117.25 price target. Key developments include executive transitions and ongoing Kenvue acquisition negotiations with EU regulators.
KMB presents a mixed investment case with attractive 5.16% dividend yield and 54-year dividend growth streak, but faces execution risks from the Kenvue acquisition and cash flow pressures. The stock trades below analyst targets with bearish technical momentum, requiring careful monitoring of merger integration and cash flow sustainability for dividend investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
